RAR Agonists for Aortic Valve Calcification and Bioprosthetic Durability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aortic valve calcification, particularly calcific aortic valve disease (CAVD), lack targeted medical therapies to prevent, slow down, or treat fibrocalcific AVS, and bioprosthetic valve degeneration due to tissue calcification, with bioprosthetic valves experiencing long-term failure.
Innovation Solution
Administering a therapeutically effective amount of retinoic acid receptor (RAR) agonists to patients, either systemically or locally through bioprosthetic valves, to reverse, prevent, or delay aortic valve calcification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bioprosthetic valves are used to treat aortic valve stenosis, then valve replacement is achieved, but long-term failure occurs due to structural valve deterioration from tissue calcification
Solution Approach 1:
The patent applies parameter changes by modulating the biochemical environment to alter calcification progression. Specifically, it uses retinoic acid receptor agonists to change the cellular phenotype and metabolic state of valvular interstitial cells, thereby modifying the calcification process parameters to prevent bioprosthetic valve deterioration
Solution Approach 2:
The patent employs retinoic acid receptor agonists as intermediary substances that mediate between the valve tissue and the harmful calcification process. These agonists bind to nuclear receptors in valvular interstitial cells, triggering intracellular signaling pathways that inhibit osteoblastic differentiation and calcification, thus protecting the valve from structural deterioration
2Ease of manufacture
If no targeted medical therapy is used, then current treatment options are limited to valve replacement, but this results in long-term failure due to calcification
Solution Approach 1:
The patent replaces the mechanical approach of valve replacement with a biochemical therapy approach. Instead of surgically or catheter-based mechanical intervention, it uses pharmacological agents (retinoic acid receptor agonists) to target and modify the underlying calcification process at the cellular level, offering a non-invasive medical treatment option
Solution Approach 2:
The patent changes the biochemical parameters of valve cell metabolism by introducing retinoic acid receptor agonists. These agonists alter gene expression patterns in valvular interstitial cells, specifically downregulating osteoblastic markers and inhibiting calcification pathways, thereby transforming the disease progression trajectory without surgical intervention
3Object-generated harmful factors
If retinoic acid is administered, then calcification is reduced, but the mechanism involves complex cellular and molecular pathways
Solution Approach 1:
The patent uses retinoic acid receptor agonists as intermediary molecules that simplify the complex calcification process into a controllable biochemical pathway. These agonists bind to nuclear receptors, which then act as transcription factors to regulate specific genes involved in calcification, thereby providing a targeted and manageable mechanism to inhibit the complex multistep calcification process
Solution Approach 2:
The patent modifies key biochemical parameters in valvular interstitial cells by introducing retinoic acid receptor agonists. This changes the cellular phenotype from a calcific to a non-calcific state by altering gene expression profiles, specifically reducing osteoblastic differentiation markers and inhibiting mineralization pathways, thereby controlling calcification through controlled biochemical parameter changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
RAR agonists effectively reduce calcification and osteoblast-like phenotypes in valvular interstitial cells, potentially preventing or delaying aortic valve stenosis and bioprosthetic valve degeneration.
Implementation Method 1
Retinoic pathway has documented effects on inflammatory, fibrotic, angiogenesis and calcifying processes in other cells that VIC. For example, retinoid acid, the bioactive metabolic of vitamin A, inhibits osteoblastic mineralization (Lind, 2013) and reduces the expression of osteoprotegerin through activation of retinoid acid receptors in osteoblasts (Jacobson, 2004).
Implementation Method 2
retinoid acid is a negative regulator of osteoblast differentiation and inhibits calcifications in mesenchymal progenitor cells which have same properties than VIC to differentiate (Green, 2017).
Data Source
AI summary
Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve—a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.